.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Novartis
AstraZeneca
UBS
Baxter
Boehringer Ingelheim
McKinsey
Dow
Cantor Fitzgerald
Queensland Health

Generated: December 16, 2017

DrugPatentWatch Database Preview

Pernix Ireland Pain Company Profile

« Back to Dashboard

What is the competitive landscape for PERNIX IRELAND PAIN, and when can generic versions of PERNIX IRELAND PAIN drugs launch?

PERNIX IRELAND PAIN has one approved drug.

There are thirteen US patents protecting PERNIX IRELAND PAIN drugs.

There are one hundred and fifty-two patent family members on PERNIX IRELAND PAIN drugs in thirty-four countries.

Summary for Pernix Ireland Pain

International Patents:152
US Patents:13
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pernix Ireland PainZOHYDRO ERhydrocodone bitartrateCAPSULE, EXTENDED RELEASE;ORAL202880-001Oct 25, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Pernix Ireland PainZOHYDRO ERhydrocodone bitartrateCAPSULE, EXTENDED RELEASE;ORAL202880-001Oct 25, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Pernix Ireland PainZOHYDRO ERhydrocodone bitartrateCAPSULE, EXTENDED RELEASE;ORAL202880-001Oct 25, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Pernix Ireland PainZOHYDRO ERhydrocodone bitartrateCAPSULE, EXTENDED RELEASE;ORAL202880-004Oct 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Pernix Ireland PainZOHYDRO ERhydrocodone bitartrateCAPSULE, EXTENDED RELEASE;ORAL202880-001Oct 25, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Pernix Ireland PainZOHYDRO ERhydrocodone bitartrateCAPSULE, EXTENDED RELEASE;ORAL202880-003Oct 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Pernix Ireland PainZOHYDRO ERhydrocodone bitartrateCAPSULE, EXTENDED RELEASE;ORAL202880-001Oct 25, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Pernix Ireland PainZOHYDRO ERhydrocodone bitartrateCAPSULE, EXTENDED RELEASE;ORAL202880-001Oct 25, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Pernix Ireland PainZOHYDRO ERhydrocodone bitartrateCAPSULE, EXTENDED RELEASE;ORAL202880-005Oct 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Pernix Ireland PainZOHYDRO ERhydrocodone bitartrateCAPSULE, EXTENDED RELEASE;ORAL202880-006Oct 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for PERNIX IRELAND PAIN drugs

Drugname Dosage Strength Tradename Submissiondate
hydrocodone bitartrateExtended-release Capsules10 mg, 15 mg, 20 mg, 30 mg, 40 mg, and 50 mgZOHYDRO ER2/26/2014

Non-Orange Book Patents for Pernix Ireland Pain

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,730,325 Multiparticulate modified release composition► Subscribe
9,421,201Treating pain in patients with hepatic impairment► Subscribe
8,119,163Nanoparticulate and controlled release compositions comprising cefditoren► Subscribe
9,522,147Treating pain in patients with hepatic impairment► Subscribe
7,580,712Wireless high-speed data network planning tool► Subscribe
6,793,936 Multiparticulate modified release composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Pernix Ireland Pain Drugs

Country Document Number Estimated Expiration
Mexico2007016151► Subscribe
Australia2006285349► Subscribe
Israel196066► Subscribe
Australia2006343445► Subscribe
Colombia5261536► Subscribe
Australia2005247019► Subscribe
Canada2653839► Subscribe
European Patent Office1126826► Subscribe
European Patent Office2311442► Subscribe
BrazilPI0609982► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Novartis
Baxter
Cerilliant
Deloitte
US Army
Argus Health
Cipla
UBS
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot